Sellas Announces Positive Survival Results in AML Trial
SELLAS Life Sciences announced positive Phase 2 trial data for SLS009 (tambiciclib), a CDK9 inhibitor, in relapsed/refractory acute myeloid...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
SELLAS Life Sciences announced positive Phase 2 trial data for SLS009 (tambiciclib), a CDK9 inhibitor, in relapsed/refractory acute myeloid...
Opus Genetics announced positive one-month data from the first pediatric patient in its Phase 1/2 trial of OPGx-LCA5, a...
Recursion Pharmaceuticals has dosed the first patient in a Phase 1 clinical trial, EXCELERIZE, for REC-3565, a potential best-in-class...
Real-world evidence (RWE) is increasingly referenced in regulatory conversations, particularly following the FDA’s 2023 guidance. Roche’s recent FDA clearance...
Multinational clinical trials are crucial for advancing medical innovation and improving patient outcomes. By including diverse populations, they provide...
NKGen Biotech announced updated Phase 1 clinical trial data for troculeucel, an NK cell therapy for moderate Alzheimer’s disease....
ALX Oncology received FDA clearance for its Investigational New Drug (IND) application for ALX2004, an antibody-drug conjugate (ADC) designed...
Teva Pharmaceuticals has submitted a supplemental Biologics License Application to the FDA for AJOVY (fremanezumab-vfrm) to prevent episodic migraines...
Reunion Neuroscience presented the design of its REKINDLE Phase 2 clinical trial, which will evaluate RE104 for treating adjustment...
TG Therapeutics announced the publication of two articles, one examining the evolution of CD20 treatments for multiple sclerosis (MS)...